Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
OCUP
OCUP | US
1.33
USD0.01
0.76%
OCUP | US
About OCUP
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
1.33
Open
1.35
High
1.35
Low
1.28
Ocuphire Pharma Inc. a clinical-stage ophthalmic biopharmaceutical company focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops a once-daily preservative-free eye drop formulation of phentolamine mesylate for dim light or night vision disturbances; and for pharmacologically induced mydriasis and presbyopia. The company also develops APX3330 a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. The company is headquartered in Farmington Hills Michigan.
View LessOCUP | US
Risk
44.1
Sharpe
-0.96
Luna's Score
42/100
Recommendation
Sell
Luna says (OCUP | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
38.3%1 month
44.1%3 months
68.5%6 months
70.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
12.00
Price to book
0.83
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-2.55
Ent. to rev.
0.20
PEG
-
Other Fundamentals
EBITDA
-15.07M
MarketCap
34.84M
MarketCap(USD)
34.84M
Div. yield
-
Op. margin
-748.92
Erngs. growth
-
Rev. growth
-69.70
Ret. on equity
-36.01
Short ratio
10.10
Short perc.
3.74
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.18
Range1M
0.22
Range3M
0.94
Volumes: Market Activity
Rel. volume
0.80
Price X volume
92.67K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.55 | 0.53 | Cheaper |
| Ent. to Revenue | 0.20 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.83 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 68.49 | 72.80 | Par |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 34.84M | 3.66B | Emerging |
